Predict your next investment

Venture Capital
avlar.com

See what CB Insights has to offer

Investments

27

Portfolio Exits

8

Funds

2

Partners & Customers

1

About Avlar BioVentures

Avlar is a biotechnology venture capital company which currently has over Euro150 million under management in Avlar BioVentures Fund I, Avlar BioVentures Fund II and the First Cambridge Gateway Fund. The funds are focused on seed and early-stage investments and are used to invest in biopharmaceutical, small molecule drug discovery, epigenetics, medtech and related biotechnology opportunities, and some technology ventures.

Avlar BioVentures Headquarter Location

Highfield Court Church Lane

Cambridge, England, CB23 8AG,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Avlar BioVentures Investments

27 Investments

Avlar BioVentures has made 27 investments. Their latest investment was in Medical Device Innovations as part of their Seed VC on November 11, 2011.

CBI Logo

Avlar BioVentures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/28/2011

Seed VC

Medical Device Innovations

$0.7M

Yes

10/12/2009

Seed VC

Crescendo Biologics

$7.1M

Yes

1

10/22/2007

Series A

CellCentric

$4.3M

No

7/6/2006

Series D

Subscribe to see more

$99M

Subscribe to see more

10

10/25/2005

Seed VC

Subscribe to see more

$99M

Subscribe to see more

0

Date

11/28/2011

10/12/2009

10/22/2007

7/6/2006

10/25/2005

Round

Seed VC

Seed VC

Series A

Series D

Seed VC

Company

Medical Device Innovations

Crescendo Biologics

CellCentric

Subscribe to see more

Subscribe to see more

Amount

$0.7M

$7.1M

$4.3M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

0

Avlar BioVentures Portfolio Exits

8 Portfolio Exits

Avlar BioVentures has 8 portfolio exits. Their latest portfolio exit was Paradigm Therapeutics on April 02, 2007.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/2/2007

Acquired

$99M

4/25/2005

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

12/22/2004

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

7/27/2004

IPO

Subscribe to see more

$99M

Subscribe to see more

0

3/5/2004

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/2/2007

4/25/2005

12/22/2004

7/27/2004

3/5/2004

Exit

Acquired

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

0

0

0

10

Avlar BioVentures Fund History

2 Fund Histories

Avlar BioVentures has 2 funds, including Avlar BioVentures Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/27/2001

Avlar BioVentures Fund II

Early-Stage Venture Capital

Closed

$60.82M

1

2/1/2000

Avlar BioVentures Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

7/27/2001

2/1/2000

Fund

Avlar BioVentures Fund II

Avlar BioVentures Fund I

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$60.82M

$99M

Sources

1

10

Avlar BioVentures Partners & Customers

1 Partners and customers

Avlar BioVentures has 1 strategic partners and customers. Avlar BioVentures recently partnered with Excalibur on .

Date

Type

Business Partner

Country

News Snippet

Sources

Partner

Slovakia (Slovak Republic)

Avlar Bioventures and Excalibur Fund Managers, the. Revenue Sharing and Co-Development Agreement with ERGOMED.

based life science venture capital groups and Ergomed , an international provider of drug development services announced today that they have entered an agreement to carry out a Phase II study with Oral BVT .115959 - a novel A2A agonist in diabetic neuropathic pain .

1

Date

Type

Partner

Business Partner

Country

Slovakia (Slovak Republic)

News Snippet

Avlar Bioventures and Excalibur Fund Managers, the. Revenue Sharing and Co-Development Agreement with ERGOMED.

based life science venture capital groups and Ergomed , an international provider of drug development services announced today that they have entered an agreement to carry out a Phase II study with Oral BVT .115959 - a novel A2A agonist in diabetic neuropathic pain .

Sources

1

Avlar BioVentures Team

3 Team Members

Avlar BioVentures has 3 team members, including current Owner, Alan Goodman.

Name

Work History

Title

Status

Alan Goodman

Owner

Current

David A Gough

Chief Executive Officer

Former

Huw Jones

Chief Financial Officer

Former

Name

Alan Goodman

David A Gough

Huw Jones

Work History

Title

Owner

Chief Executive Officer

Chief Financial Officer

Status

Current

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.